1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Poland Pharmaceuticals and Healthcare Report Q1 2016

Poland Pharmaceuticals and Healthcare Report Q1 2016

  • November 2015
  • -
  • Business Monitor International
  • -
  • 86 pages

Includes 3 FREE quarterly updates

BMI View: The Polish healthcare system faces significant reform under the newly elected Law and Justiceparty. We believe that a transition from Poland's current insurance based healthcare system to a taxfinanced healthcare system will be broadly positive for all stakeholders, including the pharmaceuticalsector, as it will provide a more stable and larger source of revenue. Reimbursement criteria will also beloosened for innovative drugs, which in turn will be beneficial for multinational drugmakers operating inPoland.

Headline Expenditure Projections

- Pharmaceuticals: PLN32.04bn (USD10.15bn) in 2014 to PLN33.39bn (USD8.91bn) in 2015; +4.2% inlocal currency terms and -12.2% in US dollar terms. Forecast unchanged from last quarter.

- Healthcare: PLN111.53bn (USD35.35bn) in 2014 to PLN115.81bn (USD30.92bn) in 2015; +3.8% inlocal currency terms and -12.5% in US dollar terms. Forecast in line with last quarter.

Table Of Contents

Poland Pharmaceuticals and Healthcare Report Q1 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Poland 2013-2019) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Poland 2011-2019) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Poland 2011-2019) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Poland 2011-2019) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Poland 2011-2019) 16
Prescription Drug Market Forecast 17
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Poland 2011-2019) 18
Patented Drug Market Forecast 19
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Poland 2011-2019) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Poland 2011-2019) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Poland 2011-2019) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Poland 2013-2019) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Poland 2013-2019) 28
Industry Risk Reward Index 29
Central And Eastern Europe Risk/Reward Index - Q1 2016 29
Poland Risk/Reward Index 36
Rewards 36
Risks 36
Regulatory Review 38
Advertising Regulations 39
Other Regulatory Developments 40
Intellectual Property Regime 41
Pricing And Reimbursement 43
Pricing Regime 44
Reimbursement Regime 46
Market Overview 52
Healthcare Sector 52
Table: Civilian Outpatient Facilities, 2002-2009 55
Table: Healthcare Resources (Poland 2009-2014) 56
Table: Healthcare Personnel (Poland 2009-2014) 57
Table: Healthcare Activity (Poland 2009-2014) 57
Research and Development 60
Clinical Trials 60
Epidemiology 62
Competitive Landscape 64
Research-Based Industry 64
Table: Multinational Market Activity 65
Pharmaceutical Distribution 67
Pharmaceutical Retail Sector 68
Table: Number Of Pharmacies In Poland, 2004-2009 69
Company Profile 70
Polpharma 70
Bioton 72
Demographic Forecast 75
Demographic Outlook 75
Table: Population Headline Indicators (Poland 1990-2025) 76
Table: Key Population Ratios (Poland 1990-2025) 76
Table: Urban/Rural Population and Life Expectancy (Poland 1990-2025) 77
Table: Population By Age Group (Poland 1990-2025) 77
Table: Population By Age Group % (Poland 1990-2025) 78
Glossary 80
Methodology 82
Pharmaceutical Expenditure Forecast Model 82
Healthcare Expenditure Forecast Model 82
Notes On Methodology 83
Risk/Reward Index Methodology 84
Index Overview 85
Table: Pharmaceutical Risk/Reward Index Indicators 85
Indicator Weightings 86

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.